1. Monash Health
  2. Monash Health research
  3. Articles
Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/42793
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLau G.-
dc.contributor.authorDrummond J.-
dc.contributor.authorZhukova N.-
dc.contributor.authorWood P.-
dc.contributor.authorJanson L.-
dc.date.accessioned2021-09-03T01:09:19Z-
dc.date.available2021-09-03T01:09:19Z-
dc.date.copyright2021-
dc.date.created20210812-
dc.date.issued2021-08-12en
dc.identifier.citationPediatric Blood and Cancer. 68 (9) (no pagination), 2021. Article Number: e29094. Date of Publication: September 2021.-
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/42793-
dc.publisherJohn Wiley and Sons Inc-
dc.relation.ispartofPediatric Blood and Cancer-
dc.subject.meshbrain cancer/di [Diagnosis]-
dc.subject.meshbrain cancer/dt [Drug Therapy]-
dc.subject.meshbrain cancer/rt [Radiotherapy]-
dc.subject.meshcancer growth-
dc.subject.meshcancer palliative therapy-
dc.subject.meshcancer recurrence-
dc.subject.meshchoroid plexus tumor/di [Diagnosis]-
dc.subject.meshchoroid plexus tumor/dt [Drug Therapy]-
dc.subject.meshchoroid plexus tumor/rt [Radiotherapy]-
dc.subject.meshDNA methylation-
dc.subject.meshdrug megadose-
dc.subject.meshfatigue/si [Side Effect]-
dc.subject.meshhistopathology-
dc.subject.meshinduction chemotherapy-
dc.subject.meshminimal residual disease-
dc.subject.meshmultiple cycle treatment-
dc.subject.meshnausea/dt [Drug Therapy]-
dc.subject.meshnausea/si [Side Effect]-
dc.subject.meshpalliative therapy-
dc.subject.meshpersonalized medicine-
dc.subject.meshpromoter region-
dc.subject.meshschool triplet chemotherapy-
dc.subject.meshtumor vascularization-
dc.subject.meshcarboplatin/pv [Special Situation for Pharmacovigilance]-
dc.subject.meshcelecoxib/cb [Drug Combination]-
dc.subject.meshcelecoxib/dt [Drug Therapy]-
dc.subject.meshcelecoxib/pv [Special Situation for Pharmacovigilance]-
dc.subject.meshcisplatin/cb [Drug Combination]-
dc.subject.meshcisplatin/dt [Drug Therapy]-
dc.subject.meshcisplatin/pv [Special Situation for Pharmacovigilance]-
dc.subject.meshcyclophosphamide/cb [Drug Combination]-
dc.subject.meshcyclophosphamide/dt [Drug Therapy]-
dc.subject.meshcyclophosphamide/pv [Special Situation for Pharmacovigilance]-
dc.subject.meshetoposide/ae [Adverse Drug Reaction]-
dc.subject.meshetoposide/cb [Drug Combination]-
dc.subject.meshetoposide/dt [Drug Therapy]-
dc.subject.meshetoposide/cv [Intracerebroventricular Drug Administration]-
dc.subject.meshetoposide/pv [Special Situation for Pharmacovigilance]-
dc.subject.meshfenofibrate/cb [Drug Combination]-
dc.subject.meshfenofibrate/dt [Drug Therapy]-
dc.subject.meshfenofibrate/pv [Special Situation for Pharmacovigilance]-
dc.subject.meshmethotrexate/cb [Drug Combination]-
dc.subject.meshmethotrexate/dt [Drug Therapy]-
dc.subject.meshmethotrexate/pv [Special Situation for Pharmacovigilance]-
dc.subject.meshmethylated DNA protein cysteine methyltransferase/ec [Endogenous Compound]-
dc.subject.meshondansetron/dt [Drug Therapy]-
dc.subject.meshondansetron/pv [Special Situation for Pharmacovigilance]-
dc.subject.meshprotein p53/ec [Endogenous Compound]-
dc.subject.meshthalidomide/cb [Drug Combination]-
dc.subject.meshthalidomide/dt [Drug Therapy]-
dc.subject.meshthalidomide/pv [Special Situation for Pharmacovigilance]-
dc.subject.meshthiotepa/ae [Adverse Drug Reaction]-
dc.subject.meshthiotepa/cb [Drug Combination]-
dc.subject.meshthiotepa/dt [Drug Therapy]-
dc.subject.meshthiotepa/cv [Intracerebroventricular Drug Administration]-
dc.subject.meshthiotepa/pv [Special Situation for Pharmacovigilance]-
dc.subject.meshtopotecan/ae [Adverse Drug Reaction]-
dc.subject.meshtopotecan/cb [Drug Combination]-
dc.subject.meshtopotecan/dt [Drug Therapy]-
dc.subject.meshtopotecan/cv [Intracerebroventricular Drug Administration]-
dc.subject.meshtopotecan/pv [Special Situation for Pharmacovigilance]-
dc.subject.meshvincristine/cb [Drug Combination]-
dc.subject.meshvincristine/dt [Drug Therapy]-
dc.subject.meshvincristine/pv [Special Situation for Pharmacovigilance]-
dc.subject.meshOmmaya reservoir-
dc.titleTriple intraventricular chemotherapy for treatment of relapsed choroid plexus carcinoma. [Pediatric Blood and Cancer]-
dc.typeLetter-
dc.type.studyortrialCase series or case report-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1002/pbc.29094-
dc.publisher.placeUnited States-
dc.identifier.pubmedid34003555 [http://www.ncbi.nlm.nih.gov/pubmed/?term=34003555]-
dc.identifier.institution(Lau, Drummond, Janson) Pharmacy Department, Monash Health, Clayton, VIC, Australia-
dc.identifier.institution(Zhukova, Wood) Children's Cancer Centre, Monash Children's Hospital/Monash Health, Clayton, VIC, Australia-
dc.identifier.institution(Zhukova, Wood) Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, VIC, Australia-
dc.identifier.institution(Wood) Department of Paediatrics, Monash University, VIC, Australia-
dc.subect.keywordscase report-
dc.subect.keywordsclinical article-
dc.subect.keywordshuman-
dc.subect.keywordsletter-
dc.subect.keywordsmale-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeLetter-
item.cerifentitytypePublications-
crisitem.author.deptPaediatric - Haematology-Oncology (Children's Cancer Centre)-
Appears in Collections:Articles
Show simple item record

Page view(s)

22
checked on Nov 24, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.